Ann: AGM Chair's address and CEO's presentation, page-18

I would encourage everyone to write to the ASX about this ‘one minute to midnight’ partnership termination but given only a handful of shareholders could even be bothered submitting on online Q to the AGM I’m not holding my breath.

And the funny thing is @col69 that if you look at the diagram below, the no-licence fee and no-milestone deal with Medicxi is the most advanced partnership even though it’s still in a pre-clinical phase. Whereas the ongoing multi-year research agreements with Genentech and MSD are both way behind. Perhaps these two partnerships are still in the research phase and not even in pre-clinical.

The pumper has gone quiet. Probably licking his post-AGM wounds before his next pump campaign. Less than 4 weeks to go before his 92 cents share price prediction is due to materialise.